As previously reported, TD Cowen upgraded Ascendis Pharma to Buy from Hold with a price target of $175, up from $156. The firm says its more positive sentiment on the TransCon PTH launch is driven by expectations for approval by the August 14 PDUFA deadline with a clean label, including no black box or REMS, and higher price of $200,000 per year based on Yorvipath’s premium to Natpara in the EU. The firm is increasing its TransCon PTH peak estimate to EUR 1.4B, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
- Ascendis Pharma Updates Corporate Financial Strategy
- Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Ascendis presents new data/results of Phase 1/2 IL-Believe Trial at ASCO
- Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024